According to the Zhitong Finance App, Kang Feng Bio-B (06922) announced interim results for the six months ended June 30, 2026. The group obtained revenue of RMB 406.79 million (same unit), a year-on-year decrease of 20.4%; the owner of the parent company should have accounted for a loss of 1.582 million yuan, a decrease of 36.68% over the previous year; and a loss of 0.06 yuan per share.

According to the announcement, the decline in revenue was mainly due to the Group actively adjusting its sales strategy in the first half of 2026 to better meet the development needs of the industry. As a result, the Group's sales declined compared to the same period last year.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.